About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Exosome as the Prognostic and Predictive Biomarker in EBC Patients

NCT05955521·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Samsung Medical Center

Age

Any age

Sex

FEMALE

Healthy volunteers

Accepted

You may be eligible if

Early breast cancer
Planned neoadjuvant chemotherapy
Triple negative breast cancer or HER2-positive breast cancer

You may not be if

Stage IV breast cancer
Hormone receptor positive breast cancer

The record

StatusActive not recruiting

PhaseNo phase

Taking part200

StartedMay 2021

UpdatedJul 21, 2023

Conditions

Triple Negative Breast Cancer HER2-positive Breast Cancer

Where1

Ji-Yeon Kim
Seoul, South Korea

Clareo Health | Exosome as the Prognostic and Predictive Biomarker in EBC Patients